Download PDF
kleintier konkret 2021; 24(02): 20-30
DOI: 10.1055/a-1319-9941
Pharmakotherapie
Hund.Katze

Personalisierte Medizin in der Pharmakotherapie: Wie weit sind wir in der Veterinärmedizin?

Joachim Geyer
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Die personalisierte Medizin soll für jeden Patienten eine optimale Therapie ermöglichen. Dies erfordert, dass individuelle Unterschiede in der Arzneimittelantwort bekannt sind und vor Therapiebeginn auch diagnostisch bestimmt werden können. In der Veterinärmedizin ist dies aktuell nur in sehr wenigen Fällen (z. B. beim sog. MDR1-Defekt) möglich, in den nächsten Jahren werden aber große Fortschritte erwartet.

Publication History

Article published online:
19 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Mealey KL, Martinez SE, Villarino NF. et al. Personalized medicine: going to the dogs?. Human Genetics 2019; 138: 467-481
    CrossrefPubMedGoogle Scholar
  • 2 Fink-Gremmels J. Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. Eur J Pharmacol 2008; 585: 502-509
    CrossrefPubMedGoogle Scholar
  • 3 Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4-33
    CrossrefPubMedGoogle Scholar
  • 4 Ma Q, Lu AYH. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63: 437-459
    CrossrefPubMedGoogle Scholar
  • 5 Ferraldeschi R, Newman WG. Pharmacogenetics and pharmacogenomics: a clinical reality. Ann Clin Biochem 2011; 48: 410-417
    CrossrefPubMedGoogle Scholar
  • 6 Fleischer S, Sharkey M, Mealey K. et al. Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model. AAPS J 2008; 10: 110-119
    CrossrefPubMedGoogle Scholar
  • 7 Toutain PL, Ferran A, Bousquet-Melou A. Species differences in pharmacokinetics and pharmacodynamics. Handb Exp Pharmacol 2010; 199: 19-48
    CrossrefPubMedGoogle Scholar
  • 8 Kakehi M, Ikenaka Y, Nakayama SMM. et al. Uridine diphosphate-glucuronosyltransferase (UGT) xenobiotic metabolizing activity and genetic evolution in pinniped species. Toxicol Sci 2015; 147: 360369
    CrossrefPubMedGoogle Scholar
  • 9 Shrestha B, Reed JM, Starks PT. et al. Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: phylogenetic timing and the role of hypercarnivory. PLoS One 2011; 6 (03) e18046
    CrossrefPubMedGoogle Scholar
  • 10 Ramirez CJ, Minch JD, Gay JM. et al. Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats. Pharmacogenet Genomics 2011; 21: 66-75
    CrossrefPubMedGoogle Scholar
  • 11 Mise M, Hashizume T, Matsumoto S. et al. Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 2004; 14: 769-773
    CrossrefPubMedGoogle Scholar
  • 12 Martinez SE, Andresen MC, Zhu Z. et al. Pharmacogenomics of poor drug metabolism in Greyhounds: Cytochrome P450 (CYP) 2B11 genetic variation, breed distribution, and functional characterization. Sci Rep 2020; 10: 69
    CrossrefPubMedGoogle Scholar
  • 13 Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K. et al. Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica 2000; 30: 575-588
    CrossrefPubMedGoogle Scholar
  • 14 Martinez SE, Shi J, Zhu HJ. et al. Absolute quantitation of drug-metabolizing cytochrome P450 enzymes and accessory proteins in dog liver microsomes using label-free standard-free analysis reveals interbreed variability. Drug Metab Dispos 2019; 47: 1314-1324
    CrossrefPubMedGoogle Scholar
  • 15 Blaisdell J, Goldstein JA, Bai SA. Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 1998; 26: 278-283
    PubMedGoogle Scholar
  • 16 Perez Jimenez TE, Mealey KL, Schnider D. et al. Identification of canine cytochrome P-450 s (CYPs) metabolizing the tramadol (+)-M1 and (+)-M2 metabolites to the tramadol (+)-M5 metabolite in dog liver microsomes. J Vet Pharmacol Ther 2018; 41: 815-824
    CrossrefPubMedGoogle Scholar
  • 17 Roussel F, Duignan DB, Lawton MP. et al. Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 1998; 357: 27-36
    CrossrefPubMedGoogle Scholar
  • 18 Paulson SK, Engel L, Reitz B. et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 1999; 27: 1133-1142
    PubMedGoogle Scholar
  • 19 Martinez MN, Antonovic L, Court M. et al. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab Rev 2013; 45: 218-230
    CrossrefPubMedGoogle Scholar
  • 20 Trepanier LA, Ray K, Winand NJ. et al. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 1997; 54: 73-80
    CrossrefPubMedGoogle Scholar
  • 21 Mealey KL. Pharmacogenetics. Vet Clin North Am Small Anim Pract 2006; 36: 961-973
    CrossrefPubMedGoogle Scholar
  • 22 Geyer J, Janko C. Treatment of MDR1 mutant dogs with macrocyclic lactones. Curr Pharm Biotechnol 2012; 13: 969-986
    CrossrefPubMedGoogle Scholar
  • 23 Court MH, Greenblatt DJ. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics 2000; 10: 355-369
    CrossrefPubMedGoogle Scholar
  • 24 Graham MJ, Bell AR, Crewe HK. mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica 2003; 33: 225-237
    CrossrefPubMedGoogle Scholar
  • 25 Witherock VJ, Morgan DG, Lentz KA. et al. Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs. Drug Metab Dispos 2012; 40: 228-231
    CrossrefPubMedGoogle Scholar
  • 26 Aretz JS, Geyer J. Detection of the CYP1A2 1117C>T polymorphism in 14 dog breeds. J Vet Pharmacol Ther 2011; 34: 98-100
    CrossrefPubMedGoogle Scholar
  • 27 Aleman M, Nieto JE, Magdesian KG. Malignant hyperthermia associated with ryanodine receptor 1 (C7360 G) mutation in Quarter Horses. J Vet Intern Med 2009; 23: 329-334
    CrossrefPubMedGoogle Scholar